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1. Introduction 
This report summarizes the key developments during 2012 in the international governance of 
biosafety, agricultural biotechnology and genetically modified organisms (GMOs). This year was 
one of relative quiet, with no major political controversies or breakthroughs in the international 
law arena. 
 
2. Global Uptake Status of Commercialized Biotech/GM Crops in 2012 
GMOs have now been on the market for 17 years, and some GM crops varieties have reached 
nearly 100% market domination in a number of countries. According to the annual global status 
report by the International Service for the Acquisition of Agri-biotech Applications (ISAAA), 
the extraordinary growth trend in the global uptake of GM crops continued during 2012. This 
year’s new record of 170.3 million hectares of planted GM crops represents a 100-fold increase 
from the 1.7 million hectares planted in the introduction year 1996. Moreover, during the past 17 
years, the accumulated worldwide hectarage has grown to 1.7 billion ha – equivalent to an area 
50% larger than the total land-mass of the US or China. Despite these impressive growth 
numbers, the annual increase rates seems to be slowing slightly. After nearly a decade-and-a-half 
of double digit growth numbers, in the last two year this have slowed to respectively 8% and 6% 
annual increase. Perhaps this is indicative that the commercialization peak has nearly been 
reached and market saturation may be in sight, unless new crops and novel traits (perhaps more 
consumer-benefit oriented) are developed.  
The ISAAA further reports that the number of countries reporting cultivation of GM crops 
decreased slightly from 29 to 28, of which 20 were developing countries (growing 52% of the 
global total). Sudan and Cuba joined as newcomers while Sweden and Germany discontinued 
their cultivation of GM potatoes. The top ten of GM growing countries remained virtually 
unchanged from previous years, led by the United States (69.5 million ha), followed by Brazil 
(36.6 mio ha), Argentina (23.9 mio ha), Canada (11.6 mio ha), India (10.8 mio ha), China (4 mio 
ha), Paraguay (3.4 mio ha), South Africa (2.9 mio ha), Pakistan (2.8 mio ha), and Uruguay (1.4 
mio ha).  
 
3. Renationalization of GMO Regulation in the European Union?  
Europe continues to be largely a no-go area for GM crops, with only a rather symbolic total of 
129,071 ha of GM maize planted throughout the entire continent, of which 90% in Spain, and 
marginal plots in Portugal, the Czech Republic, Romania and Slovakia (see ISAAA report, 
above). Even those small plantings may disappear if Monsanto’s MON810 maize variety, 
approved in 1998, its pending re-authorization is not successful (the original permit expired in 
2008 and the crop is currently marketed under a controversial indefinite extension rule until the 
EU renews the permit). The only other GM crop authorized for cultivation in the European (EU), 
the Amflora potato which in March 2010 was the first new GM crop to receive approval in over 
ten years, was definitively pulled off the market by its producer BASF in early 2012 because of 
lack of market interest and fierce civil society opposition. Moreover, some 10 EU Member States 
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have so-called precautionary ‘safeguard bans’ against growing GM crops, Norway has a 
restrictive regime and Switzerland has a full moratorium in place.  
The EU Member States have for the past two years been mulling a contentious new regulatory 
framework, proposed by the EU Commission in July 2010 (see COM(2010)375 final, and 
COM(2010)380 final). According to the Commission, the scheme would leave in place the 
current EU-level authorization procedure for GMOs, but would provide Member States with 
reservations regarding GM crops the flexibility to restrict or prohibit their cultivation on their 
national territory. However, the proposal has been received with much skepticism and confusion 
and indeed, despite its ostensible simplicity and brevity, the Commission’s reform package 
seems rather to raise more questions than it answers, in both legal and political terms. This is 
exemplified by the heated inter-institutional (legal) altercations that have ensued, with the expert 
legal services of each EU institution and many Member States shedding highly diverging light on 
the proposal, and providing their respective interpretations of the legal validity and solidity of the 
proposed reform. What is more, vocal stakeholder involvement (including civil society 
organizations but also, notably the biotech industry, led by EuropaBio), academic criticism, and 
popular media attention has further ignited this debate in the public domain. Serious doubts have 
been raised about the legal solidity of the scheme, in particular as regards the compatibility of 
such national restrictions or bans with EU and international/WTO trade law. After all, the large 
number of national bans under the existing regulatory framework were already subject of legal 
dispute in the WTO, in the EC – Biotech Products dispute brought by the US, Canada and 
Argentina against the EU and individual banning Member States. Given this large number of 
existing bans, the EU Commission’s proposal may be no more than a codification or (ex post) 
legitimization of the political status quo of (re)nationalized opposition to GMOs in Europe, but 
some fear that it might in fact be a strategic ploy by the EU Commission to break the 
longstanding deadlock in EU-level decisionmaking, while offering no new legal grounds or 
protection to precautious Member States to ward off legal action in EU or WTO courts. It is clear 
that the EU finds itself at a crossroads, in deciding whether to continue down the road of EU 
integration (a road that has been thus far been riddled with obstacles and potholes), or whether to 
veer off into the direction of national differentiation (at the risk of further fragmentation and 
disharmony). For the moment, and for the foreseeable future, the Commission’s ‘Janus-faced’ 
‘new approach’ proposal seems to have further complicated this decision, and has exacerbated 
the political standoff, rather than to appease it. No doubt, international trade partners, most 
notably the complainants in the previous EC – Biotech Products case, will be following 
developments in the EU with great interest, ready to make their way back to the WTO in 
Geneva. 
  
 
3. Cartagena Protocol on Biosafety (BSP) 
The Cartagena Protocol on Biosafety (BSP) to the Convention on Biological Diversity (CBD) is 
the main international instrument for regulation of biosafety and GMOs. The Protocol’s 
membership of ratifying or accepting Parties has grown to 164, with Bahrain and Jamaica joining 
during 2012. The BSP has been in force since September 2003. 
In October 2012, the Conference of the Parties (COP) to CBD serving as the Meeting of the 
Parties to the Cartagena Protocol on Biosafety convened for its sixth meeting (COP/MOP 6), in 
Hyderabad, India.  
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Meetings in the context of the BSP had in previous years taken place under increasing pressures 
and contention, in the build-up towards the adoption of the long-awaited supplementary protocol 
on liability and redress. Now that Parties were able to conclude this instrument at COP/MOP-5, 
in October 2010, as the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress 
to the Cartagena Protocol on Biosafety – NKLSPLR (Annex to Decision BS-V/11: International 
rules and procedures in the field of liability and redress for damage resulting from transboundary 
movements of living modified organisms, available at: 
http://bch.cbd.int/protocol/NKL_Protocol.shtml; for discussion, see last year’s biosafety report in 
this Yearbook), the pressure was off, as reflected both in the agenda and the general atmosphere 
at COP/MOP-6 in Hyderabad (Report UNEP/CBD/BS/COP-MOP/6/18, 21 November 2012; see 
also ENB summary meeting report Vol. 9 No. 585, available at: 
http://www.iisd.ca/download/pdf/enb09585e.pdf).  
The meeting addressed a number of standing issues on the COP/MOP agenda, including (a) 
compliance: Parties were to send their second round of national compliance reports, after a first 
round in 2007. Despite a very positive 90% submission rate, the reports showed major gaps in 
national biosafety frameworks, with only about half of the parties actually having implemented 
the core provisions of the Protocol by establishing an advance informed agreement procedure 
and implementing national biosafety frameworks. This led to a call on Parties to expedite efforts 
to put in place legal and administrative frameworks to meet obligations under the Protocol, and 
relatedly the need for financial resources for parties experiencing difficulties implementing the 
Protocol; the importance of developing public awareness programmes, etc; (b) operation and 
activities of the Biosafety Clearing-House (BCH); (c) financial mechanisms and resources: the 
COP/MOP noted with concern the drastic decline in the level of bilateral and multilateral 
funding available 
for biosafety capacity-building activities and urged Parties to give priority to national biosafety 
plans and projects under the Global Environment Facility (GEF) System for Transparent 
Allocation of Resources (GEF-STAR) to ensure support for the BSP’s implementation; (d) 
cooperation with other organizations, conventions and initiatives; (e) and budgetary and 
administrative matters. The meeting also addressed a number of substantive issues that will 
come/continue to dominate the agenda in the years to come, including the longstanding 
controversial issue of handling, transport, packaging and identification (HTPI) requirements for 
shipments of living modified organisms (LMOs). They key issues in the HTPI dossier are the 
documentation requirements for shipments of LMOs intended for direct use as food or feed (LMOs-
FFPs), under Article 18(2) BSP. Arduous negotiations had previously led to the adoption of the so-
called ‘Curitiba rules’ at COP/MOP-3 in 2006, but the question of whether a stand-alone document 
should be required for such shipments or whether existing documentation would suffice was 
ultimately deferred by Parties to COP/MOP-6, based on the experiences gained from the review of 
the second round of national reporting on this issue by Parties in 2012. According to the second 
round of national implementation reports, less than half of the parties have taken measures to 
meet the existing HTPI requirements. Discussions on HTPI requirements for LMOs-FFPs have 
again been deferred for discussion at COP/MOP-7 (which will take place either in 2014 or 2015, 
depending on whether the meeting frequency will be adjusted, as is being debated). Hence, 
discussions in Hyderabad focused on HTPI requirements for LMOs destined for contained use or 
for intentional release. Following discussions on whether to include references to independent 
documentation as types of acceptable documentation, and to the LMO-quick link tool, Parties 
ultimately deciding to include neither of these, instead pragmatically opting for full flexibility by 
allowing both/either commercial invoices or standalone documentation for HTPI purposes. 
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Lengthy discussions were also held about coding systems and LMO databases, and on the 
question of whether to include a reference to the UN Model Regulations on Transport of 
Dangerous Goods, but following opposition by, inter alia, Paraguay, Uruguay, 
Mexico, Colombia, Nigeria and New Zealand, no such reference was ultimately included – again 
illustrative of the conflict-averse, pragmatic stance that seems to now dominate BSP discussions. 
Similarly, discussions on risk assessment and risk management, in particular the revised 
guidance on risk assessment of LMOs (UNEP/CBD/BS/COP-MOP/6/13/Rev.1 and 13/Add.1), 
ended in anti-climax due to an (overly?) pragmatic approach. Despite the extensive work carried 
out to review the guidance by the Ad Hoc Technical Expert Group (AHTEG) on Risk 
Assessment as well as extensive online forums, the Parties after long discussions ultimately 
could not (yet) agree to endorse the guidance. Support for such progress came from, in particular 
the EU, Central and Eastern European countries (CEE), the African Group, Norway, China and 
Colombia, whereas New Zealand, Brazil, Ecuador, India, South Africa and the Philippines 
preferred further testing and refining of the guidance before it could be endorsed. The 
unsatisfactory compromise result of long and protracted negotiations was the “commendment” 
by the Parties of progress made on the guidance, an extension of the open-ended online forum 
and the (re-)establishment of a new AHTEG, to serve until COP/MOP 7. The decision explicitly 
reiterates (in addition to the already numerous references to its voluntary nature) that the 
guidance is not prescriptive and does not impose any obligations on parties and that the guidance 
will be tested nationally and regionally for further improvement.   
After the extensive attention for liability and redress in the context of the BSP, leading up to the 
adoption of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress to the 
Cartagena Protocol on Biosafety (NKLSPLR) in 2010, the focus has now shifted to expediting 
the ratification process for this supplementary protocol. Its entry into force requires 40 
instruments of ratification or acceptance, but support for the Protocol has thus far been rather 
modest. A total of 51 States have signed the Protocol, but only 12 had ratified it by March 2013.  
Only Latvia ratified the Protocol in 2011, joined in 2012 by the Czech Republic, Mexico, 
Sweden, Norway, Syria, Bulgaria, Lithuania, Spain, and in the first months of 2013 by Albania, 
Ireland, and the European Union. The CBD Secretariat has taken various initiatives to promote 
awareness and understanding of the provisions of the NKLSPLR, with a view to facilitating its 
signature and ratification, and to achieve a timely entry into force. Notably, in May 2012, it 
organized an inter-regional workshop on capacity needs for the implementation of the 
NKLSPLR, hosted by the protocol’s first ratifying member, Latvia, as a follow up to four 
regional workshops organized in 2011. 
Other substantive issues under discussion at COP/MOP-6 included (a) capacity building 
activities; (b) notification requirements; (c) unintentional transboundary movements and 
emergency measures (Art. 17 BSP); (d) subsidiary bodies; (e) monitoring and reporting; and (f) 
assessment and review.  
Probably the most unexpected outcome of the otherwise non-eventful COP/MOP-6 meeting was 
the progress made on the consideration of socio-economic impacts of LMOs under the BSP. 
Positions on this dossier have always been quite divergent, including even on the principal point 
of whether socio-economic considerations are even within the scope of the BSP given its key 
focus on transboundary movements. However, in Hyderabad, Parties were able to reach broad 
consensus that socio-economic considerations require substantive engagement. Instrumental to 
this breakthrough seems to have been a highly successful ‘regionally-balanced’ workshop on 
capacity-building for research and information exchange on socio-economic impacts of LMOs, 
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which took place in November 2011, in New Delhi, India. Two weeks later, a further 
international workshop on socio-economic impacts of GM crops took place in Seville, Spain, co-
organized by the European Commission's Joint Research Centre (JRC) and the UN’s Food and 
Agriculture Organization (FAO). As a first concrete step on this issue (for which a 
guidance/guidelines is foreseen as the end-product), Parties established an AHTEG that will 
endeavour to develop conceptual clarity on what exactly constitutes socio-economic 
considerations under Art. 26 BSP. No doubt, the well-known dividedness will again firmly take 
root once substantive negotiations proceed on the subject, but an important, principal step was 
taken at COP/MOP-6 towards including socio-economic considerations under the Protocol. 
 
Although technically not within the scope of this biosafety report, given its related relevance it is 
worth mentioning that the other supplementary protocol adopted at COP/MOP-5, the Nagoya 
Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising 
from their Utilization, is discussed in further detail in the annual report on the CBD, by Elisa 
Morgera and Elsa Tsioumani.  
 
 
3. Aarhus Convention and Public Participation in GMO Decision-making 
During 2012, there were no noteworthy developments as regards public participation in GMO 
decision-making in the context of the Convention on Access to Information, Public Participation 
in Decision-Making and Access to Justice in Environmental Matters (Aarhus Convention). 
Public participation in GMO decision-making has been an issue of debate under the Aarhus 
Convention since its inception, resulting in May 2005 in the adoption of the so-called ‘Almaty 
GMO Amendment’ to Convention by the second meeting of the Parties (MOP-2), with the 
objective of strengthening the rights of the public to participate in decision-making on GMOs 
(Decision II/1, Report ECE/MP.PP/2005/2, 12 July 2005). 
However, unless and until three-quarters of the Parties ratify or accept the GMO Amendment, it 
will remain devoid of practical consequences for citizens and civil society. Support for the 
agreement appears limited. In 2012, only Ireland ratified the GMO Amendment, after no 
ratifications in 2011 and only one (Slovenia) in 2010. With the total number of ratifying Parties 
now at 27, the Almaty GMO Amendment is still one ratifying Party short of the critical mass 
required for its entry into force. Evidently, even then it will only be binding upon those Parties 
that have ratified it. In the interim, just as before the amendment was adopted, the pre-existing 
non-binding GMO Guidelines will continue to apply as a voluntary instrument. 
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